7:34 AM
 | 
Sep 14, 2018
 |  BC Extra  |  Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

Editor's Note: This article was updated on Sep 14, 2018 at 11:57 AM PDT

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with a $300 million series A round, Allogene has raised $420 million in private funding to date.

Founded in November 2017, Allogene is developing a pipeline of off-the-shelf allogeneic CAR T products spun out from Pfizer Inc. (NYSE:PFE) in April, including lead program UCART19. Pfizer had held the programs' rights under a 2014 deal with Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS).

The company's management team includes former executives of CAR T company Kite Pharma Inc., which Gilead...

Read the full 525 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >